Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients

Sara J Schonfeld; Ethel S Gilbert; Graça M Dores; Charles F Lynch; David C Hodgson; Per Hall; Hans Storm; Aage Andersen; Eero Pukkala; Eric Holowaty; Magnus Kaijser; Michael Andersson; Heikki Joensuu; Sophie D Fosså; James M Allan; Lois B Travis

doi:10.1093/jnci/djj017

Back

Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients

Journal article

Open access

Peer reviewed

Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients

Sara J Schonfeld, Ethel S Gilbert, Graça M Dores, Charles F Lynch, David C Hodgson, Per Hall, Hans Storm, Aage Andersen, Eero Pukkala, Eric Holowaty, …

JNCI : Journal of the National Cancer Institute, Vol.98(3), pp.215-218

02/01/2006

DOI: 10.1093/jnci/djj017

PMID: 16449681

Files and links (1)

url

https://doi.org/10.1093/jnci/djj017View

Published (Version of record) Open Access

Abstract

Treatments for Hodgkin lymphoma are associated with large relative risks of acute myeloid leukemia (AML), but there are few estimates of the excess absolute risk (EAR), a useful measure of disease burden. One-year Hodgkin lymphoma survivors (N = 35,511) were identified within 14 population-based cancer registries in Nordic countries and North America from January 1, 1970, through December 31, 2001. We used Poisson regression analysis to model the EAR of AML, per 10,000 person-years. A total of 217 Hodgkin lymphoma survivors were diagnosed with AML (10.8 expected; unadjusted EAR = 6.2; 95% confidence interval = 5.4 to 7.1). Excess absolute risk for AML was highest during the first 10 years after Hodgkin lymphoma diagnosis but remained elevated thereafter. In subsequent analyses, adjusted for time since Hodgkin lymphoma diagnosis and presented for the 5-9 year interval, the EAR was statistically significantly (P < .001) larger in patients diagnosed with Hodgkin lymphoma at age 35 years and older than in those diagnosed before 35 years of age. The EAR of AML declined statistically significantly after 1984 (7.0 to 4.2 and 16.4 to 9.9 in the < 35 and > or = 35 age groups, respectively), which may be associated with modifications in chemotherapy.

SEER Program

Risk Assessment

Humans

Leukemia, Myeloid, Acute - epidemiology

Middle Aged

Male

Antineoplastic Agents - administration & dosage

Incidence

Neoplasms, Second Primary - epidemiology

Confounding Factors (Epidemiology)

Antineoplastic Agents - adverse effects

Neoplasms, Second Primary - chemically induced

Hodgkin Disease - therapy

Ontario - epidemiology

Hodgkin Disease - drug therapy

Adult

Female

Poisson Distribution

Registries

North America - epidemiology

Leukemia, Myeloid, Acute - chemically induced

Finland - epidemiology

Research Design

Scandinavian and Nordic Countries - epidemiology

Details

Title: Subtitle: Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients
Creators: Sara J Schonfeld - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-7238, USA
Ethel S Gilbert
Graça M Dores
Charles F Lynch
David C Hodgson
Per Hall
Hans Storm
Aage Andersen
Eero Pukkala
Eric Holowaty
Magnus Kaijser
Michael Andersson
Heikki Joensuu
Sophie D Fosså
James M Allan
Lois B Travis
Resource Type: Journal article
Publication Details: JNCI : Journal of the National Cancer Institute, Vol.98(3), pp.215-218
DOI: 10.1093/jnci/djj017
PMID: 16449681
NLM abbreviation: J Natl Cancer Inst
ISSN: 1460-2105
eISSN: 1460-2105
Publisher: Oxford University Press; United States
Grant note: Intramural NIH HHS
Language: English
Date published: 02/01/2006
Academic Unit: Epidemiology
Record Identifier: 9983995145102771

Metrics

36 Record Views

59 Times Cited - Web of Science